Home » Stocks » CTLT

Catalent, Inc. (CTLT)

Stock Price: $119.81 USD 0.49 (0.41%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 20.41B
Revenue (ttm) 3.76B
Net Income (ttm) 496.80M
Shares Out 170.34M
EPS (ttm) 2.95
PE Ratio 40.57
Forward PE 36.36
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $119.81
Previous Close $119.32
Change ($) 0.49
Change (%) 0.41%
Day's Open 119.22
Day's Range 119.04 - 121.11
Day's Volume 920,123
52-Week Range 79.65 - 127.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Catalent's (CTLT) latest product is aimed at improving customer service by speeding up the drug substance development process.

6 days ago - Zacks Investment Research

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: HASI, IMMR, NOW, WMT
1 week ago - Zacks Investment Research

Catalent Inc (NYSE: CTLT) will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities.  The plant is curre...

1 week ago - Benzinga

Catalent's (CTLT) latest agreement is expected to lead to a prototype development of a Zydis formulation via a feasibility study.

2 weeks ago - Zacks Investment Research

Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.

Other stocks mentioned: CRDF, NVCR, NVS, OCX, PKI
4 weeks ago - Zacks Investment Research

If production setbacks can be avoided, gains should be in sight.

Other stocks mentioned: HZNP, OPK
1 month ago - The Motley Fool

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.

1 month ago - Zacks Investment Research

Catalent (CTLT) expects to strengthen its position in new therapeutic areas and boost its cell therapy portfolio via the latest acquisition.

1 month ago - Zacks Investment Research

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

1 month ago - Business Wire

AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc's (NYSE: EBS) Baltimore plant to a factory owned ...

Other stocks mentioned: AZN
1 month ago - Benzinga

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

2 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

2 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

2 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

2 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

2 months ago - Business Wire

Catalent Inc (NYSE: CTLT) has been expanding rapidly in next-gen cell therapies, and now it has added another facility in Belgium as part of its plan to bolster its E.U. hub. Catalent has acquired Prome...

2 months ago - Benzinga

Catalent (CTLT) delivered earnings and revenue surprises of 7.90% and 5.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Catalent (NYSE:CTLT) decreased 0.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 64.00% over the past year to $0.82, which beat the es...

2 months ago - Benzinga

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

2 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell ...

3 months ago - Business Wire

Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.

Other stocks mentioned: MRNA
3 months ago - Zacks Investment Research

CAMBRIDGE, Mass. & SOMERSET, N.J.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Catalent, Inc. (NYSE: CTLT), the ...

Other stocks mentioned: MRNA
3 months ago - Business Wire

Catalent to double output of Moderna vaccine: Report

YouTube video

The U.S. coronavirus vaccine supply could be getting a new boost. According to the Wall Street Journal, contract manufacturer Catalent plans to nearly double its output of the Moderna vaccine, with the ...

Other stocks mentioned: MRNA
3 months ago - CNBC Television

Catalent Inc (NYSE: CTLT) is reportedly expanding its U.S. production of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine to ensure the U.S. has ample supply as it ramps up vaccinations. Catalent helps Mod...

Other stocks mentioned: MRNA
3 months ago - Benzinga

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

4 months ago - Zacks Investment Research

Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine is expected to get a significant supply boost after manufacturing partner Catalent Inc (NYSE: CTLT) secured a key U.S. regulator clearance, Bloomberg New...

Other stocks mentioned: JNJ
4 months ago - Benzinga

TORONTO--(BUSINESS WIRE)--Cybin signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

4 months ago - Business Wire

Despite occasional pullbacks in share price, these growth stocks are expected to continue to create shareholder value during the year. The post 7 Growth Stocks With Compelling Stories appeared first on ...

Other stocks mentioned: CHWY, CRM, HACK, LOUP, ORCL, POOL
4 months ago - InvestorPlace

Catalent is scaling up manufacturing capacity for Johnson & Johnson's COVID-19 vaccine at its Italian plant, addressing some concerns over the drugmaker's ability to meet vaccine supply targets in the E...

Other stocks mentioned: JNJ
4 months ago - Reuters

Catalent Inc plans to expand its COVID-19 vaccine production in Europe that will enable it to make more doses of Johnson & Johnson's shot, the Wall Street Journal reported https://www.wsj.com/articles/c...

Other stocks mentioned: JNJ
4 months ago - Reuters

Catalent (CTLT) has been struggling lately, but the selling pressure may be coming to an end soon

4 months ago - Zacks Investment Research

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

5 months ago - Business Wire

USNA vs. CTLT: Which Stock Is the Better Value Option?

Other stocks mentioned: USNA
5 months ago - Zacks Investment Research

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, c...

5 months ago - Business Wire

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, c...

5 months ago - Business Wire

Catalent (CTLT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

5 months ago - Zacks Investment Research

Catalent, Inc. (CTLT) CEO John Chiminski on Q2 2021 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Catalent (CTLT) delivered earnings and revenue surprises of 12.50% and 1.66%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Catalent (NYSE:CTLT) moved higher by 1.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 40.00% year over year to $0.63, which beat t...

5 months ago - Benzinga

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

5 months ago - Business Wire

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell ...

6 months ago - Business Wire

Catalent is forming a base and near a possible buy zone ahead of its next quarterly earnings report, expected on or around Feb. 3. The post Earnings Season Preview: Catalent Near Buy Zone With EPS Due a...

6 months ago - Investors Business Daily

Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

6 months ago - Zacks Investment Research

Increasingly, the Wall Street firms we cover are starting to agree that while the future for the U.S.

Other stocks mentioned: CRL, FCX, NOC
6 months ago - 24/7 Wall Street

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...

6 months ago - Business Wire

Catalent (CTLT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

6 months ago - Zacks Investment Research

As is the case every year, the major Wall Street firms we cover here at 24/7 Wall St.

Other stocks mentioned: AVTR, HCA, HOLX, GH
7 months ago - 24/7 Wall Street

Does Catalent (CTLT) have what it takes to be a top stock pick for momentum investors? Let's find out.

7 months ago - Zacks Investment Research

On Friday, Catalent got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Catalent Joins Rank Of Stocks With 95-Plus Composite Rating appeared first on Investor's Business Daily.

7 months ago - Investors Business Daily

About CTLT

Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplem... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jul 31, 2014
Stock Exchange
NYSE
Ticker Symbol
CTLT
Full Company Profile

Financial Performance

In 2020, Catalent's revenue was $3.09 billion, an increase of 22.89% compared to the previous year's $2.52 billion. Earnings were $220.70 million, an increase of 60.63%.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Catalent stock is "Strong Buy." The 12-month stock price forecast is 135.20, which is an increase of 12.85% from the latest price.

Price Target
$135.20
(12.85% upside)
Analyst Consensus: Strong Buy